<DOC>
	<DOCNO>NCT02467608</DOCNO>
	<brief_summary>Assess Efficacy HUEXC030 Add-on Excipient Eradicate Anti-Tuberculosis Drugs Induced Hepatic Injury ( ATDH ) Subjects Pulmonary Tuberculosis</brief_summary>
	<brief_title>Efficacy HUEXC030 Subjects With Pulmonary Tuberculosis</brief_title>
	<detailed_description>The study drug Isoniazid formulate HUEXC030 excipient eradicate ATDH , whereas reference control Isoniazid formulate inactive excipient . Subjects fulfill entry criterion write informed consent enrol study . Eligible subject randomize 1:1 ratio receive study drug reference control drug . Subjects genotyped accord select panel single nucleotide polymorphism ( SNPs ) categorize high risk low risk group occur ATDH via specific haplotype consist CYP2E1 NAT2 SNPs . Based extensive study result 2007 2011 , estimate frequency patient bear high risk genotype Taiwanese population around 25 % . Approximately 352 subject enrol genotype screen order recruit 88 high risk subject 44 subject intervention control arm . Subjects stratify high risk group administer test drug reference control drug oral daily 6 month treatment completion , i.e . bacteriologically confirm negative active M. tuberculosis . Subjects low risk genotype remove study 8 week study treatment , return conventional TB medication care investigator least one follow-up visit 4 week End Study .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Drug-Induced Liver Injury</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Main inclusion criterion : 1 . A definite case pulmonary TB 2 . Patient expose 3 less dos firstline antiTB drug treatment current disease . 3 . Age â‰¥ 20 year 4 . Have well document baseline liver function test indicate patient 's adequate liver function enrollment study . i. AST ALT &lt; 3x ULN ii . total serum bilirubin &lt; 2.0 mg/dL Main 1 . Have alcoholic liver disease habitual alcohol consumption &gt; 30 g/day one year 2 . Previously diagnose : i. extrapulmonary TB without concomitant lung invasion ii . HIV iii . liver malignancy iv . liver cirrhosis v. systemic disease may cause liver dysfunction 3 . Documented history serious allergic reaction resistance isoniazid , rifampicin , ethambutol , pyrazinamide , sugar alcohol structurally related compound 4 . Subjects use follow therapy TB treatment start : i. antiretroviral agent ii . oral corticosteroid 5 . Subjects pregnant lactate 6 . Subjects childbearing potential committed take reliable contraception participation study least 4 week end study treatment 7 . Subjects serious disease consider investigator condition enter trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HUEXC030</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
</DOC>